17. Aug 2026
Description
(AWP Alliance News) - Sandoz entered a development, manufacturing, and commercialization collaboration with Shanghai Henlius Biotech covering up to 10 biosimilars, expanding its biosimilar pipeline to 39 assets with potential to rise to 46. Sandoz will hold commercialization rights outside China for the agreed products, while Henlius will handle development and manufacturing. The milestones-based deal carries total consideration of up to USD 322 million, including near-term payments of up to USD 100.5 million tied to the initial assets.
The first tranche includes proposed biosimilars of cetuximab, evolocumab, and belimumab, with an option for recombinant human hyaluronidase for use in subcutaneous biosimilar development.
https://www.publicnow.com/view/DBCDB19070890DF442E8C27EA384A7ABF81F54C2…
Disclaimer: This news brief was created using generative artificial intelligence. Sandoz Group AG published the original content used to generate this news brief via EQS News on August 17, 2026, and is solely responsible for the information contained therein.
